{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:14Z","timestamp":1787113634648,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116880","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:58:04Z","timestamp":1781308684000},"page":"116880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-142X","authenticated-orcid":false,"given":"Chiara","family":"Dauccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1009-3777","authenticated-orcid":false,"given":"Dominik","family":"Hlauschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"S\u00f6lkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-2118","authenticated-orcid":false,"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-0209","authenticated-orcid":false,"given":"Peter C.","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Helfgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zoppoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-8799","authenticated-orcid":false,"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-2778","authenticated-orcid":false,"given":"Laetitia","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-4309","authenticated-orcid":false,"given":"Jill","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"Luca","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116880_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejca.2026.116880_bib2","article-title":"Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis","volume":"86","author":"Dauccia","year":"2026","journal-title":"Breast Church Livingstone"},{"issue":"11","key":"10.1016\/j.ejca.2026.116880_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab023","article-title":"Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis","volume":"113","author":"Lohmann","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116880_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115489","article-title":"Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial","volume":"223","author":"Dauccia","year":"2025","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2026.116880_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-019-0687-8","article-title":"Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland","volume":"38","author":"Tenvooren","year":"2019","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejca.2026.116880_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2015.02.017","article-title":"Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejca.2026.116880_bib7","article-title":"PI3K\u03b3 within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance","volume":"108","author":"Becattini","year":"2011"},{"key":"10.1016\/j.ejca.2026.116880_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114244","article-title":"Targeting PI3K\/AKT signaling pathway in obesity","volume":"159","author":"Savova","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.ejca.2026.116880_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2026.116880_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2011.495","article-title":"Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia","volume":"31","author":"Gallagher","year":"2012","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejca.2026.116880_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-1080","article-title":"Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors","volume":"7","author":"Juric","year":"2017","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.ejca.2026.116880_bib12","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0613","article-title":"Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor\u2013positive advanced breast cancer","volume":"24","author":"Dickler","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2026.116880_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30334-1","article-title":"Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Saura","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116880_bib14","unstructured":"World health organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. 2016."},{"issue":"12","key":"10.1016\/j.ejca.2026.116880_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116880_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.499","article-title":"Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer","volume":"109","author":"Pfeiler","year":"2013","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2026.116880_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116880_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-022-00633-1","article-title":"At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy","volume":"19","author":"Vasan","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116880_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940939","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer","volume":"12","author":"du Rusquec","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116880_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75154-1","article-title":"Higher risk of recurrence in early-stage breast cancer patients with increased levels of ribosomal protein S6","volume":"14","author":"Cascardo","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2026.116880_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-010-1315-z","article-title":"Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer","volume":"126","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ejca.2026.116880_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.4579","article-title":"Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116880_bib23","doi-asserted-by":"crossref","DOI":"10.2337\/dc06-2544","article-title":"Effect of BMI on lifetime risk for diabetes in the U.S","volume":"30","author":"Narayan","year":"2007","journal-title":"Diabetes Care"},{"issue":"ement_1","key":"10.1016\/j.ejca.2026.116880_bib24","first-page":"S167","article-title":"8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20132025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ejca.2026.116880_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116880_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116880_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/ni.2343","article-title":"Immunological complications of obesity","volume":"13","author":"Kanneganti","year":"2012","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116880_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01624-5","article-title":"Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study","volume":"25","author":"Masala","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.116880_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-021-03881-3","article-title":"Mammographic density to predict response to neoadjuvant systemic breast cancer therapy","volume":"148","author":"Di Cosimo","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116880_bib30","article-title":"Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients","volume":"32","author":"Skarping","year":"2021","journal-title":"Cancer Causes Control"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:13:31Z","timestamp":1787112811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"alternative-id":["S0959804926006611"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116880","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116880"}}